JAK2V617F: You can't have too much

Blood

Volumn 111, Issue 8, 2008, Pages 3913-

  Levine, Ross L ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENE; GENE DOSAGE; GENE EXPRESSION; GENE LOCUS; GENE MUTATION; HEMATOPOIETIC CELL; HUMAN; JAK2 GENE; JAK2V617F GENE; MPL GENE; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; NONHUMAN; NOTE; PHENOTYPE; POLYCYTHEMIA VERA; PRIORITY JOURNAL; RETROVIRUS; THROMBOCYTHEMIA; TRANSGENE;

EID: 78650759098     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-01-133322     Document Type: Note

References (5)

1. PardananiA,FridleyBL,LashoTL,GillilandDG,TefferiA.Host genetic variation contributes to phentypic diversity in myeloproliferative disorder.Blood 2008;111:2785-2789.
2. Scott LM, Scott MA, Campbell PJ, Green AR. Progenitors homozygous for the V617F mutation occur in most patients with pohlcythrnia vera, but not essential thrombocythemia. Blood. 2006; 108:2435 2437.
3. Scott LM, Tong W, LevineRL, et al, JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis, N Engl J Med. 2007:356:459-468.
4. Pikman V,LeeBH, MercherT, et al. .MPLW515L, is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3:e270.
5. pardanani AD,Levine RL, LashoT,et al MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients Blood.2006;108:3472-3476.